JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Quanterix Corp

Închisă

SectorSănătate

6.49 2.37

Rezumat

Modificarea prețului

24h

Curent

Minim

6.23

Maxim

6.62

Indicatori cheie

By Trading Economics

Venit

-3.5M

-34M

Vânzări

16M

40M

Marjă de profit

-83.479

Angajați

471

EBITDA

5.7M

-31M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+18.3% upside

Dividende

By Dow Jones

Următoarele câștiguri

16 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

85M

323M

Deschiderea anterioară

4.12

Închiderea anterioară

6.49

Sentimentul știrilor

By Acuity

50%

50%

147 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 feb. 2026, 23:52 UTC

Achiziții, Fuziuni, Preluări

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb. 2026, 23:52 UTC

Achiziții, Fuziuni, Preluări

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb. 2026, 23:23 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb. 2026, 22:57 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb. 2026, 21:51 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 feb. 2026, 21:49 UTC

Câștiguri

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb. 2026, 21:39 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:36 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb. 2026, 21:34 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:28 UTC

Achiziții, Fuziuni, Preluări

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb. 2026, 21:23 UTC

Câștiguri

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb. 2026, 21:19 UTC

Câștiguri

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb. 2026, 21:17 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb. 2026, 21:17 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:10 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:08 UTC

Câștiguri

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb. 2026, 21:07 UTC

Câștiguri

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q EPS 24c >PLTR

2 feb. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

18.3% sus

Prognoză pe 12 luni

Medie 7.5 USD  18.3%

Maxim 8 USD

Minim 7 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

147 / 352 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat